These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 22915637)

  • 1. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
    Radich JP; Kopecky KJ; Appelbaum FR; Kamel-Reid S; Stock W; Malnassy G; Paietta E; Wadleigh M; Larson RA; Emanuel P; Tallman M; Lipton J; Turner AR; Deininger M; Druker BJ
    Blood; 2012 Nov; 120(19):3898-905. PubMed ID: 22915637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
    Kantarjian H; Shah NP; Hochhaus A; Cortes J; Shah S; Ayala M; Moiraghi B; Shen Z; Mayer J; Pasquini R; Nakamae H; Huguet F; Boqué C; Chuah C; Bleickardt E; Bradley-Garelik MB; Zhu C; Szatrowski T; Shapiro D; Baccarani M
    N Engl J Med; 2010 Jun; 362(24):2260-70. PubMed ID: 20525995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
    Kantarjian H; Cortes J; Kim DW; Dorlhiac-Llacer P; Pasquini R; DiPersio J; Müller MC; Radich JP; Khoury HJ; Khoroshko N; Bradley-Garelik MB; Zhu C; Tallman MS
    Blood; 2009 Jun; 113(25):6322-9. PubMed ID: 19369231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
    Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
    Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
    Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
    Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
    Chuah CT; Nakamae H; Shen ZX; Bradley-Garelik MB; Kim DW
    Leuk Lymphoma; 2014 Sep; 55(9):2093-100. PubMed ID: 24289108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
    Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
    Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
    Kim SH; Menon H; Jootar S; Saikia T; Kwak JY; Sohn SK; Park JS; Jeong SH; Kim HJ; Kim YK; Oh SJ; Kim H; Zang DY; Chung JS; Shin HJ; Do YR; Kim JA; Kim DY; Choi CW; Park S; Park HL; Lee GY; Cho DJ; Shin JS; Kim DW
    Haematologica; 2014 Jul; 99(7):1191-6. PubMed ID: 24705186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
    Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
    Kantarjian H; Pasquini R; Lévy V; Jootar S; Holowiecki J; Hamerschlak N; Hughes T; Bleickardt E; Dejardin D; Cortes J; Shah NP
    Cancer; 2009 Sep; 115(18):4136-47. PubMed ID: 19536906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
    Deininger MW; Kopecky KJ; Radich JP; Kamel-Reid S; Stock W; Paietta E; Emanuel PD; Tallman M; Wadleigh M; Larson RA; Lipton JH; Slovak ML; Appelbaum FR; Druker BJ
    Br J Haematol; 2014 Jan; 164(2):223-32. PubMed ID: 24383843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
    Jabbour E; Kantarjian HM; Saglio G; Steegmann JL; Shah NP; Boqué C; Chuah C; Pavlovsky C; Mayer J; Cortes J; Baccarani M; Kim DW; Bradley-Garelik MB; Mohamed H; Wildgust M; Hochhaus A
    Blood; 2014 Jan; 123(4):494-500. PubMed ID: 24311723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
    Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
    Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
    Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
    Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
    N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
    Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
    Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
    Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.